Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar
RecruitingNCT06817161Phase: PHASE3Started 2025-04-30
Summary
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line
Eligibility
Sex
FEMALE
Min Age
18 Years
Max Age
None
Locations
Centre François BaclesseCaen, France
CHU CAENCaen, France
Centre Oscar LambretLille, France
Centre Henri BecquerelRouen, France
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT06817161